Phase Forward Launches Empirica Study Solution

Phase Forward has launched Empirica Study, formerly the Clinical Trials Signal Detection product (CTSD). The product helps clinical and safety teams to improve their understanding of a product’s emerging safety profile during clinical development, by facilitating the timely detection, review and analysis of safety issues in clinical trials data.

Empirica Study joins the Empirica Signal and Empirica Trace products to round out Phase Forward’s Empirica Suite, which supports safety review and risk management across the product development lifecycle, from clinical trials through post-marketing.

Empirica Study provides a visual data environment for reviewing safety data and detecting signals in trial data in CDISC Study Data Tabulation Model (SDTM) format.

Chan Russell, President of Lincoln Safety Group, Phase Forward, said: “With the increased availability of standardized data in CDISC format, study sponsors have even greater opportunities to delve into clinical data, surfacing potential safety issues earlier in the process.”

“Using its statistical analysis algorithms, Empirica Study helps safety experts examine the most critical safety concerns and make informed decisions regarding the risk/benefit ratios of products in development,” he added.